Introduction
============

Natural products originate as secondary metabolites from a myriad of sources, including terrestrial plants, animals, marine organisms, microorganisms, terrestrial vertebrates and invertebrates ([@B37]). These structurally and chemically diverse molecules act as a remarkable class of therapeutics to heal various ailments. The earliest documentation of the application of natural products to improve human health dates back to the ancient Mesopotamia's sophisticated medicinal system from 2900 to 2600 BCE ([@B24]; [@B218]). By the early 1900's, approximately 80% of all medicines were obtained from plant sources ([@B228]; [@B218]). The discovery of penicillin from *Penicillium notatum* by Alexander Fleming in 1928 marked a significant shift from plants to microorganisms as a source of natural products ([@B70]). Since then, microorganism-derived compounds have been utilized in medicine, agriculture, food industry and scientific research ([@B202]). The early years of antibiotic research discovered streptomycin from *Streptomyces* *griseus* ([@B259]), chloramphenicol from *Streptomyces venezuelae* ([@B58]), chlortetracycline from *Streptomyces aureofaciens* ([@B61]), cephalosporin C from *Cephalosporium acremonium* ([@B174]), erythromycin from *Saccharopolyspora erythraea* and vancomycin from *Amycolatopsis orientalis* ([@B77]). Given these historical successes, large pharmaceutical companies have continued to invest in this traditional domain ([@B54]). Currently, approximately 60% of approved small molecule medicines are related to natural products, and 69% of all antibacterial agents originate from natural products ([@B191]; [@B145]). However, many natural compounds with potential as novel drug candidates occur in low concentrations in nature, often making drug discovery and development burdensome and economically impractical. Therefore, an emerging alternative solution is to express biosynthetic genes from the original producers in microbial hosts, notably bacteria and fungi ([@B230]). Engineered microbes can produce appreciable amounts of scarce natural compounds, thereby facilitating the synthesis of the target novel compound and potent derivatives, as well as the validation of their activities ([@B145]).

The natural product sector is not the only area that has undergone substantial growth or utilizes therapeutic products generated in/from living organisms. Prokaryotic and eukaryotic microbial cells, in combination with the advancement of recombinant DNA techniques, have been responsible for an explosion of biologics. Biologics are a set of molecules whose active pharmaceutical ingredients are derived from living organisms such as animals, plants, microorganisms, human blood products, and tissue transplants that are too complex to be produced through organic synthesis ([@B198]). They can be categorized into five main classes: (1) monoclonal antibodies, like trastuzumab (Herceptin^®^) and rituximab (Rituxan^®^); (2) blood factor derivatives, like coagulation factor VIIa (NovoSeven RT^®^) and epoiten alfa (Epogen^®^); (3) vaccines; (4) enzymes; and (5) recombinant proteins, such as immunomodulatory cytokines, and thrombolytic agents ([@B128]). Since the approval of recombinant human insulin and recombinant human growth hormone as some of the first modern biopharmaceuticals, large numbers of additional biopharmaceuticals have been developed, approved, and marketed using different microbial expression systems; many more are currently in the development pipeline ([@B85]). After the successful production of the recombinant human insulin Humulin^®^, *Escherichia coli* quickly became the prevalent expression platform in the 1980s when the biopharmaceutical sector emerged and was followed by yeast *Saccharomyces cerevisiae* ([@B203]). Microbial cells constitute the majority of hosts employed in the production of currently approved recombinant pharmaceuticals for human treatment, mainly because of their lack of unconventional post-translational modifications, proteolytic instability, poor solubility and activation of cell stress responses ([@B85]). This demonstrates that microbial hosts represent convenient and robust platforms for the efficient production of recombinant proteins despite some bottlenecks and obstacles.

Herein, we will summarize the biological activities and applications of a variety of natural products and biologics and review the microbial systems used to produce these pharmaceutical compounds. We will also cover past and current attempts at improving the microbial production of these biological molecules and generating new molecules using diverse engineering approaches. In addition, we will discuss the challenges of the production of natural products and biologics in microbial systems and advances that can help overcome them for drug discovery and development. Future prospects for cutting-edge developments and technological advances in microbial production of bioactive natural products and recombinant proteins as the most valuable sources of therapeutics are also discussed.

Biological Activities of Natural Products and Biologics
=======================================================

Natural products have diverse biological activities relevant to human health, including antibiotic, antifungal, anticancer, immunosuppressive, anti-inflammatory, biofilm inhibitory activities, etc. In this section, we will focus on the biological activities of natural products, which can be grouped into several categories. The biological activities of microbial recombinant proteins will be also reviewed.

Antibiotics
-----------

Natural products are a rich source for antibiotic drug development, but the most clinically useful of these scaffolds can be classified as polyketides, non-ribosomal peptides, and aminoglycosides ([@B271]). Polyketides, assembled by polyketide synthases (PKS), make up one of the largest classes of chemically diverse natural products and are among the most important secondary metabolites for their applications in medicine, agriculture, and industry ([@B237]). For example, pikromycin was the first known polyketide antibiotic produced from *S. venezuelae* in 1950 ([@B254]; [@B110]). It has been reported that pikromycin is very potent against multi-drug resistant respiratory pathogens ([@B270]). Another remarkable polyketide antibiotic with significant clinical applications is erythromycin A (1; [Figure 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}), which was first discovered in 1952 as a broad-spectrum antibiotic produced by *S. erythraea* ([@B150]). This antibiotic is prescribed to a treat wide variety of bacterial infections, such as respiratory and gastrointestinal infections, whooping cough, syphilis, and acne, especially in patients who have adverse reactions against penicillin ([@B39]). While many natural antibiotics fail to inhibit Gram-negative organisms, tetracyclines (2; [Figure 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}) are active against both Gram-positive and Gram-negative bacteria ([@B38]; [@B50]).
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###### 

Biological activities of microbial-derived natural products and biologics.

  Name                                             Origin                                                                                                                                       Biological activity                                                                                                                                                 References
  ------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------
  **Antibiotic**                                                                                                                                                                                                                                                                                                                                                    
  Erythromycin A (1)                               *Saccharopolyspora erythraea*                                                                                                                Antibacterial                                                                                                                                                       [@B150]; [@B283]; [@B39]
  Tetracycline (2)                                 *Streptomyces rimosus*                                                                                                                       Antibacterial                                                                                                                                                       [@B38]; [@B50]
  Vancomycin (3)                                   *Amycolatopsis orientalis*                                                                                                                   Antibacterial                                                                                                                                                       [@B77]; [@B45]
  Streptomycin (4)                                 *Streptomyces* *griseus*                                                                                                                     Antibacterial                                                                                                                                                       [@B206]; [@B259]
  Nisin A (5)                                      *Lactococcus lactis*                                                                                                                         Antimicrobial                                                                                                                                                       [@B134]; [@B89]
  Reuterin (6)                                     *Lactobacillus reuteri*                                                                                                                      Antimicrobial                                                                                                                                                       [@B239]; [@B89]
  **Antifungal Agents**                                                                                                                                                                                                                                                                                                                                             
  Amphotericin B (7)                               *Streptomyces nodosus*                                                                                                                       Antifungal                                                                                                                                                          [@B2]; [@B244]
  Ieodoglucomide C (8)                             *Bacillus licheniformis*                                                                                                                     Antifungal                                                                                                                                                          [@B243]
  **Anticancer and Antitumor**                                                                                                                                                                                                                                                                                                                                      
  Bleomycin (9)                                    *Streptoalloteichus hindustanus*, *Streptomyces verticillus*                                                                                 Squamous cell carcinomas, Hodgkin's lymphomas and testis tumors                                                                                                     [@B62]; [@B52]
  Ddaunorubicin (10)                               *Streptomyces peucetius* and various related strains                                                                                         Acute lymphoblastic or myeloblastic lymphoma                                                                                                                        [@B53]; [@B78]
  **Immunosuppressant/Anti-inflammatory Agents**                                                                                                                                                                                                                                                                                                                    
  Rapamycin (11)                                   *Streptomyces rapamycinicus* (formerly, *Streptomyces hygroscopicus* ATCC 29253),*Streptomyces iranensis*, and *Actinoplanes* sp. N902-109   Immunosuppressive, antifungal, antitumor, neuroprotective, neuroregenerative, and lifespan extension activities, growth inhibitory activity against several fungi   [@B255]; [@B141]; [@B129]; [@B182]; [@B4]; [@B231]; [@B276]
  FK506 (12)                                       *Streptomyces tsukubaensis* and several *Streptomyces* species                                                                               Immunosuppressive, antifungal, anti-inflammatory, neuroprotective and neuroregenerative activities, rheumatoid arthritis treatment                                  [@B241]; [@B141]; [@B156]; [@B51]; [@B11]; [@B276]
  **Biofilm-Inhibitory Agents**                                                                                                                                                                                                                                                                                                                                     
  Cahuitamycins (13)                               *Streptomyces gandocaensis*                                                                                                                  Inhibitors of *Acinetobacter baumannii* biofilms                                                                                                                    [@B189]
  **Others**                                                                                                                                                                                                                                                                                                                                                        
  Avermectins (14)                                 *Streptomyces avermitilis*                                                                                                                   Onchocerciasis and lymphatic filariasis                                                                                                                             [@B213]
  Mollemycin A 20 (15)                             *Streptomyces* sp. (CMB-M0244)                                                                                                               Gram-positive and Gram-negative bacteria, antimalarial activity                                                                                                     [@B20]
  Lipstatin (16)                                   *Streptomyces toxytricini*                                                                                                                   Pancreatic lipase inhibitor for obesity and diabetes                                                                                                                [@B265]; [@B202]
                                                                                                                                                                                                                                                                                                                                                                    

As previously mentioned, penicillin is a well-known antibiotic secondary metabolite from *P. notatum* and is effective against Gram-positive bacteria, which are responsible for diseases such as scarlet fever, pneumonia, gonorrhea, meningitis, and diphtheria ([@B71]; [@B240]). Penicillin belongs to non-ribosomal peptide antibiotics along with vancomycin ([@B68]). Non-ribosomal peptides, assembled by non-ribosomal peptide synthetase (NRPS), possess bioactivity that can be exploited for therapeutic applications and are amongst the most widespread and structurally diverse secondary metabolites. Vancomycin (3; [Figure 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}) is another potent non-ribosomal peptide against pathogenic bacteria, including *Clostridium difficile*, *Listeria monocytogenes*, *Streptococcus pneumoniae*, *Staphylococcus epidermidis*, and methicillin-resistant *Staphylococcus aureus* (MRSA) ([@B45]).

Aminoglycosides are another class of antibiotics that act by binding to the rRNA subunit of the 30S bacterial ribosome and inhibiting protein synthesis ([@B160]). Streptomycin (4; [Figure 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}) produced by *S. griseus* is the first aminoglycoside discovered in 1944 and effective against pulmonary tuberculosis ([@B206]). Since the discovery of streptomycin, aminoglycoside antibiotics such as kanamycin, gentamicin, sisomicin, and lividomycin have been discovered and widely used to treat infectious organisms that have developed resistance against streptomycin after prolonged use ([@B187]). Despite their excellent antibacterial activity, aminoglycosides have met with resistant organisms. In order to combat antibiotic resistance to aminoglycoside antibiotics, semi-synthetic aminoglycoside antibiotics were specifically tailored to shield against these enzymes ([@B250]). Semi-synthetic aminoglycoside antibiotics such as amikacin, netilmicin, dibekacin, and isepamicin are developed as a result of semi-synthetic derivatives of the natural product ([@B157]; [@B132]).

Natural antimicrobials have also been important to the food industry in terms of food safety against foodborne pathogens. Microbes such as lactic acid bacteria, produce a wide range of chemicals that have been shown to inhibit the growth and development of other microbial species. Nisin A (5; [Figure 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}), a bacteriocin produced by *Lactococcus lactis*, is approved to preserve food in over 50 countries and is very active against Gram-positive bacteria resistant to conventional antibiotics ([@B134]; [@B89]). Reuterin (6; [Figure 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}) from *Lactobacillus reuteri* has been shown to have antimicrobial activities against foodborne pathogens and spoilage organisms when evaluated in milk, dairy, and meat products ([@B239]; [@B89]).

Antifungal Agents
-----------------

Nystatin, one of the first effective polyene antifungal agent, was obtained from *Streptomyces noursei* in 1950 and effective against *Aspergillus* species ([@B233]). Clinically, nystatin plays a significant role as a topical antifungal agent in treating oral, gastro-intestinal, and genital candidosis ([@B69]). Amphotericin B (7; [Figure 2](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}) is also a traditional polyene antifungal product of *Streptomyces nodosus* utilized against life-threatening fungal infections caused by *Aspergillus* species, and especially effective in patients who have undergone organ transplantation, received aggressive chemotherapy or with acquired immunodeficiency syndrome ([@B2]; [@B244]).
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Recently, in a review of natural products with anti-*Candida albicans* activity, 71 substances of the 142 evaluated were determined to have antifungal activity under the criteria of having minimum inhibitory concentration (MIC) values below 8 mg/mL ([@B290]). The glycolipids ieodoglucomide C (8; [Figure 2](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}) and ieodoglycolipid were isolated from the marine bacterium *Bacillus licheniformis* and exhibited antifungal activities with a 21 μg/L MIC against *Aspergillus niger*, *Rhizoctonia solani*, *Botrytis cinerea*, *Colletotrichum acutatum*, and *C. albicans* ([@B243]). Both ieodoglucomide C and ieodoglycolipid also exhibit good antibiotic properties against *S. aureus*, *Bacillus subtilis*, *Bacillus cereus*, *Salmonella typhi*, *E. coli* and *Pseudomonas aeruginosa* with MICs ranging from 0.01 to 0.05 μM, establishing these compounds as strong potential candidates for the development of new fungicides ([@B243]).

Anticancer Agents
-----------------

There are many microbe-derived anticancer agents that have been evaluated through clinical trials. For instance, the polyketide actinomycin was isolated from *Streptomyces parvulus* in 1940 and was the first antibiotic shown to have anticancer activity ([@B260]; [@B99]). In particular, actinomycin D, also known as dactinomycin, is approved by FDA and has been widely used in clinical practice as an anticancer drug for treating many tumors, such as Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma, and metastatic, non-seminomatous testicular cancer.

Another notable example is the therapeutic combination of the microbial product bleomycin (9; [Figure 2](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}), the plant compound etoposide, and the synthetic agent cisplatin, which has played a significant role in increasing the cure rate for disseminated testicular cancer from 5% in 1974 to 90% in 2011 ([@B62]; [@B52]). Bleomycin is a glycopeptide produced by *Streptoalloteichus hindustanus* and has been used for squamous cell carcinomas, melanomas, sarcomas, testicular, and ovarian cancer, Hodgkin's and non-Hodgkin's lymphomas, and testis tumors as an anticancer agent ([@B52]). Its derivative, blenoxane is also used clinically with other compounds against lymphomas, skin carcinomas, and tumors of the head, neck, and testicles ([@B52]). The anthracyclines are also an important family of polyketides produced by *Streptomyces* species by iterative PKS pathways and include daunorubicin (10; [Figure 2](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}) ([@B53]), epirubicin ([@B32]), and doxorubicin ([@B153]). The FDA approved the use of daunorubicin and doxorubicin for cancer therapy in the 1960s. Daunorubicin is used in the treatment of acute lymphoblastic or myeloblastic lymphoma. Meanwhile, doxorubicin is used in the treatment of breast cancer, solid tumors in children, soft tissue sarcomas, and aggressive lymphomas ([@B78]).

Among numerous recent examples, rapamycin, wortmannin, and geldanamycin have been found to have antiproliferative activities during clinical use as novel chemotherapeutic agents ([@B44]). Rapamycin, a natural product derived from *Streptomyces rapamycinicus* has anticancer activity in addition to its immunosuppressive, anti-inflammatory, and antifungal activities ([@B121]). It performs antitumor activity on a tumor cell by hindering its proliferation, triggering apoptosis, and inhibiting angiogenesis ([@B129]). Wortmannin is a fungal furanosteroid derivative of *Penicillium funiculosum* ([@B46]). It has shown as an effective selective inhibitor of phosphoinositide 3-kinases (PI3Ks) and PI3K- related enzymes which are play a key role in intracellular signaling pathways ([@B219]). A study on the proliferation and apoptosis of human breast MCF-7 cells treated with wortmannin uncovered that wortmannin shows antitumor activity by triggering apoptosis and impeding proliferation of cancer cells by suppressing PI3K/Akt signaling and NF-κB protein expression ([@B279]). Geldanamycin is a benzoquinone ansamycin antitumor compound derived from *Streptomyces hygroscopicus* var. *geldanus* ([@B223]). Geldanamycin prevents ATPase activity by binding to the heat shock protein and hindering the stability and function of oncogenic protein kinases involved in signal amplification cascade that controls proliferation and apoptosis ([@B223]). Geldanamycin and its analogs play a key role as anticancer agent in multiple myeloma, breast, and prostate cancer ([@B83]). Another example is epothilone, an anticancer agent produced from mycobacterium *Sorangium cellulosum*. It obstructs microtubule depolymerization thereby causing G2-M interphase arrest of the cell cycle ([@B161]). There are also marine microbial natural products that have anticancer activities, such as dolastatin, which is originated from cyanobacteria of the genera *Symploca* and *Lyngbya* ([@B220]).

Immunosuppressive Agents
------------------------

Rapamycin (also known as sirolimus) (11; [Figure 3](#F3){ref-type="fig"} and [Table 1](#T1){ref-type="table"}) and FK506 (tacrolimus) (12; [Figure 3](#F3){ref-type="fig"} and [Table 1](#T1){ref-type="table"}) are microbial natural products with immunosuppressive properties. Rapamycin blocks the proliferation of most cell types in response to activation by IL-2, IL-3, platelet-derived growth factor, epidermal growth factor, and insulin ([@B255]). Rapamycin also exhibits synergism with other immunosuppressants, such as cyclosporin, to significantly reduce kidney toxicity and acute renal allograft rejection ([@B276]). This compound has been developed to coat coronary stents and prevent organ transplant rejection and lymphangioleiomyomatosis; it was approved by the FDA for wider use in 1999 ([@B141]). In addition to its immunosuppressive activity, rapamycin possesses several other biological activities, including antitumor, neuroprotective/neuroregenerative, antineoplastic, and lifespan extension activities ([@B129]; [@B182]; [@B276]).
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FK506 is also an immunosuppressive drug and was first discovered in soil samples containing *Streptomyces tsukubaensis* and several other *Streptomyces* species ([@B241]). FK506 is used to minimize organ rejection and to induce immunosuppression via calcineurin inhibition and interruption of T cell activation pathway ([@B156]). It has been demonstrated to be more effective than cyclosporin and non-toxic in low doses ([@B51]). The discovery of its immunosuppressive activity led to its use in heart, liver, and kidney transplants with overwhelming success ([@B51]). Like rapamycin, FK506 possesses various biological activities, including antifungal, anti-inflammatory, neuroprotective, and neuroregenerative activities ([@B11]).

Anti-inflammatory Agents
------------------------

Some natural products also have anti-inflammatory activities. FK506 has shown efficacy in the treatment of refractory rheumatoid arthritis, a chronic inflammatory disease ([@B156]). Rapamycin also inhibits the inflammatory response after spinal cord injury by diminishing the activation and proliferation of inflammatory cells and the expression of inflammatory cytokines, thereby reducing secondary injury in the spinal cord and providing a neuroprotective effect ([@B231]). Recently, strepsesquitriol, isolated from *Streptomyces* sp. SCSIO 10355, has been found to have anti-inflammatory activity through the inhibition of tumor necrosis factor-α production in lipopolysaccharide-activated macrophages ([@B274]). Salinamides A and B from marine *Streptomyces* sp. CNB-091 also displayed potent topical anti-inflammatory activity through a phorbol ester-induced mouse ear edema assay ([@B248]). One study evaluated 7 peptides found in the *Faecalibacterium prausnitzii* supernatant, all belonging to a protein named microbial anti-inflammatory molecule ([@B26]). These peptides were able to inhibit the NF-κB pathway *in vitro* and showed anti-inflammatory properties *in vivo* in a dinitrobenzene sulfate-induced colitis model ([@B26]).

Biofilm Inhibitory Agents
-------------------------

Parasitic microorganisms adhere to solid surfaces and form layers of a complex polysaccharide matrix called a biofilm that confers resistance against antibiotics as wells as inflicts significant chronic bacterial infections ([@B222]). Analogs of 5-benzylidene-4-oxazolidinones are small molecules derived from marine natural products. These molecules inhibit 89% of biofilm formed by MRSA at 0.78 μM and disperses pre-formed biofilms at 4.7 μM ([@B60]). A synthetic library of 2-aminoimidazole triazoles was able to successfully inhibit 94% of biofilm formation in *Acinetobacter baumannii* and MRSA at 100 μM ([@B197]). Another recent example is cahuitamycins A-C (13; [Figure 3](#F3){ref-type="fig"} and [Table 1](#T1){ref-type="table"}) derived from the marine bacterium *Streptomyces gandocaensis*. Cahuitamycins have been evaluated as inhibitors of *A. baumannii* biofilms and it has been found that cahuitamycin C shows half maximal inhibitory concentration (IC~50~) at 14.5 μM. Modifications of cahuitamycins through selective mutasynthesis have yielded cahuitamycins D and E with an increased the potency of antibiofilm activity against *A. baumannii* ([@B189]). The FDA-approved antitumor agent actinomycin D has also significant biofilm inhibitory activity against methicillin resistant- and sensitive-strains of *S. aureus* ([@B72]; [@B131]). In addition to bacterial biofilm, fungal biofilm associated with *Candida* pathogens is responsible for serious *C. albicans* infections linked to biofilm formation on medical devices. One study showed that *Lactobacillus* biosurfactants displayed high anti-adhesive biofilm formation properties against *C. albicans* and also prevented biofilm formation of *L. monocytogenes*, *Salmonella arizonae*, *E. coli*, and *S. aureus* ([@B72]).

Others
------

Natural products can also act as antiparasitic agents. The avermectins (14; [Figure 3](#F3){ref-type="fig"} and [Table 1](#T1){ref-type="table"}) and the derivative ivermectin have shown antiparasitic activity by significantly lowering the incidence of onchocerciasis and lymphatic filariasis ([@B213]). Spinosad and milbemycin also have insecticidal activity. Spinosad is a combination of spinosyn A and D, which are both produced by *Saccharopolyspora spinosa* and have insecticidal activity against livestock external parasites via the disruption of nicotinic acetylcholine receptors ([@B202]). Milbemycin is an isolated fermentation product of *S. hygroscopicus* subsp. *aureolacrimosus* that acts as an insecticide and acaricide with GABAergic activity on the post-synaptic membranes of the inhibitory motor neurons of mites and arthropods through hyperpolarization and impeding neuronal signal transduction mechanisms ([@B41]). Mollemycin A 20 (15; [Figure 3](#F3){ref-type="fig"} and [Table 1](#T1){ref-type="table"}) is a first-in-class glycol-hexadepsipeptide-polyketide from a *Streptomyces* sp. and has antibacterial properties against certain Gram-positive and Gram-negative bacteria, as well as extremely potent antimalarial activity against drug sensitive and MDR *Plasmodium falciparum* clones ([@B20]). Microbial natural products also function as enzyme inhibitors. Lipstatin (16; [Figure 3](#F3){ref-type="fig"} and [Table 1](#T1){ref-type="table"}) is a pancreatic lipase inhibitor produced by *Streptomyces toxytricini* that is used to combat obesity and diabetes by interfering with the gastrointestinal absorption of fat ([@B265]). Lipstatin contains a beta-lactone structure that is likely responsible for irreversibly binding to the active site of lipase ([@B202]).

Biological Activity of Microbial Biologics
------------------------------------------

Since Humulin^®^([Figure 4A](#F4){ref-type="fig"}) became the first recombinant biopharmaceutical as a treatment for diabetes ([@B108]), additional FDA-approved microbial biologics have been produced by *E. coli*. Somatrem (Protropin^®^) and somatropin (Humatrope^®^) are used to treat children with growth hormone deficiency ([@B7]; [@B203]). Another biopharmaceutical produced from *E. coli* is pegloticase (Krystexxa^®^) for the treatment of chronic gout and interferon (IFN) α-2b (Intron^®^A; [Figure 4B](#F4){ref-type="fig"}) for the treatment of certain types of genital warts, malignant melanoma, hairy cell leukemia, follicular lymphoma, Kaposi's sarcoma, and chronic Hepatitis B or C ([@B7]; [@B203]). Top selling biopharmaceuticals of 2015 from microorganisms include insulin glargine (Lantus^®^) derived from *E. coli*, which functions as an insulin analog, and the pneumococcal vaccines (Prevnar^®^family) derived from *S. pneumoniae* and *Corynebacterium diphtheriae* ([@B109]; [@B203]). Biopharmaceuticals are also utilized for their antitumoral properties, such as the cytokines filgrastim (Neupogen^®^) and granulocyte colony stimulating factor pegfilgrastim (Neupeg^®^; [Figure 4C](#F4){ref-type="fig"}), which are both derived from *E. coli*. Flgrastim stimulates hematopoiesis for bone marrow transplantation and cancer chemotherapy-induced neutropenia, whereas pegfilgrastim stimulates the differentiation, proliferation and activation of neutrophilic granulocytes for cancer chemotherapy-induced neutropenia ([@B203]). Recombinant human interleukin-3 (hIL-3; [Figure 4D](#F4){ref-type="fig"}) protein is a cytokine that regulates the differentiation and proliferation of the various cells of the immune system ([@B94]). The hIL-3 protein is derived from *B. subtilis*, *B. licheniformis*, and *E. coli* and has utility as a laboratory reagent in hematology for cell cultures, differentiation studies and functional assays. It has shown that hIL-3 has potential in treating bone marrow failure, hematological malignancies, and can support engraftment after bone marrow transplantation ([@B267]). In addition, recombinant *Pfs48/45* is a disulfide-rich malaria transmission-blocking vaccine produced by *L. lactis* that provides immunization against malaria from *P. falciparum* ([@B229]).
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Recombivax is produced by *S. cerevisiae* and can prevent infection of all known subtypes of the Hepatitis B virus ([@B203]). Some examples of currently approved protein therapeutics derived from yeast include human serum albumin (Recombumin^®^and Albucult^®^; [Figure 4E](#F4){ref-type="fig"}), human insulin (Actrapid^®^) and primary immunization for infants born of Hepatitis B virus (HBV) surface antigen (Pediarix^®^), all of which are obtained exclusively from *S. cerevisiae* ([@B147]; [@B10]; [@B175]; [@B169]). Recombinant human serum albumin is utilized to increase the shelf life of protein drugs by preventing physical and chemical degradation. Actrapid^®^is used to treat diabetes, and subcutaneous injections of Pediarix is designed for immunization against diphtheria, tetanus, pertussis, poliomyelitis, and infection caused by all known subtypes of HBV ([@B169]). Ecallantide (Kalbitor^®^) is an FDA-approved recombinant peptide produced by *Pichia pastoris* for the treatment of hereditary angioedema ([@B212]). Additionally, anakinra (Kineret^®^) was approved in 2001 in the United States for rheumatoid arthritis ([@B7]). Anakinra is expressed in *E. coli* and functions as an IL-1 receptor antagonist that is effective and safe for patients with systemic-onset juvenile idiopathic arthritis, adult-onset Still's disease, hereditary autoinflammatory syndromes, and Schnitzler's syndrome ([@B112]; [@B109]).

Microbial Cell Factories
========================

Selecting a suitable host strain is one of the most important aspects in the design of natural product and recombinant protein bioprocesses. We will review the characteristics of the microbial strains used to produce natural products and biologics in this section. We will also present the tools and strategies that facilitate engineering of the hosts as microbial cell factories for the production of biopharmaceutical compounds ([Table 2](#T2){ref-type="table"}).

###### 

Comparison between different microbial host systems for production of recombinant proteins and natural products.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Microbial hosts              Advantages                                                                                                                                                                                                                                                                                                      Disadvantages                                                                                                                                                                             Compounds                                                                                                                                                                                                                                                                                      References
  ---------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------
  **Gram-negative**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  *Escherichia coli*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

                               •Fast growth•Simple culture procedures•Cost-effective•High versatility of the enterobacterium and its associated systems                                                                                                                                                                                        •Lack of post-translational modifications (PTMs)•Risk of translational errors due to the presence of a large number of rare codons•Expensive and often challenging purification process   •Recombinant human insulin•Artemisinin•Erythromycin A•Somatrem•Somatropin•Pegloticase•Insulin glargine•Pneumococcal vaccines•Filgrastim•Pegfilgrastim•Human serum albumin•Hepatitis B virus immunization•IFN α-2b•IL-6                                                                         [@B108]; [@B1]; [@B35]; [@B283]; [@B67]; [@B7]; [@B109]; [@B203]

  **Gram-positive**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  *Lactococcus lactis*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

                               •Simplified downstream purification processes•Absence of endotoxins or unwanted glycosylation of proteins•Generally recognized as safe (GRAS)•Lack of secreted heterologous proteins degradation•Nisin-controlled gene expression system•Heterologous protein delivery in foodstuff or in the digestive tract   •Per liter secretion generally less robust than *Bacillus* sp.•AT-rich codon usage and/or the distribution of rare codons                                                                 •Nisin A•Pfs48/45•Enterocin A•Pediocin PA-1•IL-2•IL-6•Peanut allergen•Tetanus toxin fragment C•Transforming growth factor-β1                                                                                                                                                                   [@B234]; [@B57]; [@B144]; [@B130]; [@B155]; [@B81]; [@B162]; [@B134]; [@B136]; [@B89]; [@B19]; [@B133]; [@B229]

  *Streptomyces* sp.           •Rapid growth•Abundant supply of secondary metabolite precursors•Ability to produce natural products.•Efficient protein secretion system such as Sec pathway and twin-arginine-translocation (Tat) pathway•Well-developed genetic manipulation                                                                  •Forms pellets or clumps•Low protein yield                                                                                                                                                •Streptomycin•Pikromycin•Kanamycin•Nystatin•Anthracyclines•Rapamycin•FK506•Strepsesquitriol•Salinamides A and B•Cahuitamycin•Actinomycin D•Milbemycin•Mollemycin A•TNF α•hIL-10•Streptokinase•IL-1β•IFN-α1•Transforming growth factor-α•IL-2•IFN-α2b•Tetracycline•Daptomycin•Chloramphenicol   [@B233]; [@B115]; [@B248]; [@B141]; [@B110]; [@B41]; [@B188], [@B189]; [@B257]; [@B72]; [@B5]; [@B47]; [@B202]; [@B274]; [@B117]; [@B20]; [@B109]; [@B75]

  *Bacillus* sp.               •Outstanding fermentation properties and protein production yield (20--25 g per liter)•Completely free toxin production•Flexibility for genetic engineering•Presence of proteome secretory pathway                                                                                                              •Primarily used in Enzyme production.•Plasmid instability•Presence of proteases: leads to difficulty in the production of recombinant proteins.                                           •Ieodoglucomide C•Ieodoglycolipid•Bacillomycin D and L•Alkaline cellulose•Alkaline protease•Alkaline α-amylase•hIL-3•Fengycin•IL-1β•IFN-α2•Staphylokinase•Iturins•Surfactin                                                                                                                    [@B180]; [@B194]; [@B17]; [@B118]; [@B267]; [@B49]; [@B34]; [@B252]; [@B262]; [@B63]

  **Fungi/yeast**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  *Saccharomyces cerevisiae*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

                               •Fast growth rate•Technically practical•Cost-effective•Ability to generate post-translational modification as *O*-linked glycosylation, phosphorylation, acetylation, and acylation•Advanced fermentation science                                                                                               •*N*-linked glycosylation patterns differ from higher eukaryotes•Lack some required precursor pathways•Codon usage is biased toward A + T                                                 •Human serum albumin•Recombinant human insulin•Hepatitis B virus immunization•Artemisinic acid•Paclitaxel•hIL-6•Insulin aspart•Pfs25•Sapogenin•Saponin                                                                                                                                         [@B147]; [@B87]; [@B115]; [@B10]; [@B66]; [@B175]; [@B179]; [@B8]; [@B56]; [@B152]; [@B163]; [@B125]; [@B169]

  *Aspergillus* sp.            •GRAS status•Tolerate extreme cultivation conditions•Degrade and utilize diverse biopolymers, allowing cultivation on renewable resources•Major Source of citric acid production                                                                                                                                •Production of mycotoxins (alpha toxins)•Many host proteases•Freely dispersed filaments or highly compact pellets formed during submerged fermentations                                   •Immunoglobulin G1(κ)•Antibodies and Fab′ fragment•Bicoumanigrin•Aspernigrin B•Lactoferrin•Enniatin•Human IL-2•Human IL-6•Phytase•[L]{.smallcaps}-asparaginase•Lovastatin•Tryptostatin B                                                                                                       [@B73]; [@B30]; [@B96]; [@B183]; [@B264]; [@B86]; [@B139]; [@B192]; [@B140]; [@B154]; [@B43]

  *Hansenula polymorpha*       •GRAS status•Combined genetic manipulations, low cost screening.•Efficient fermentation properties, and protein modification•Ability to use and grow on methanol, glucose, or glycerol as its primary carbon sources•Thermo-tolerant                                                                            •The use of methanol creates hazardous conditions in lab use•Hyperglycosylation of heterologous products•Can lead to production instabilities due to sequence repetition on vector.       •IFNα-2a•Phytase•IL-6•Human serum albumin•Human hemoglobin•HBV L-protein•Hepatitis B surface antigen                                                                                                                                                                                           [@B105]; [@B76]; [@B98]; [@B42]; [@B93]; [@B164]; [@B21]; [@B126]; [@B31]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Gram-Negative Bacteria
----------------------

### Escherichia coli

*Escherichia coli* has been seen as one of the optimal systems for the production of natural products because it is easily manipulated, highly productive, there is an availability of genetic tools to use with it and there is a deep knowledge of its physiology. Artemisinin, a sesquiterpene lactone endoperoxide from *Artemisia annua* L. plants, has strong antimalarial activity against the multi-drug resistant parasite *P. falciparum* ([@B1]). Yet the synthesis of artemisinin is costly and low yields are isolated from the natural plant source. Researchers reported the production of approximately 24 mg/L of amorpha-4,11-diene (amorphadiene), an artemisinin precursor, by the expression of a codon-optimized synthetic amorphadiene synthase gene and the mevalonate pathway from *S. cerevisiae* in *E. coli*. Additionally, after further processing modifications and optimal conditions, they were able to produce 105 mg/L of artemisinic acid ([@B35]). However, there are some obstacles and limitations with *E. coli* as a dominant host in natural product biosynthesis. *E. coli* requires extensive genetic manipulation and lacks native natural product biosynthetic machinery and/or precursors. An example is phosphopantetheinyl transferase, which is responsible for the activation of the carrier protein domains of the PKSs and NRPSs. This enzyme must be introduced into *E. coli* to support of natural product biosynthesis ([@B284]). There have been efforts to overcome these hurdles, such as the production of erythromycin A and its derivatives in the engineered *E. coli* strain ([@B283]). The study generated two analogs through directed manipulation of polyketide biosynthesis in which variations were made to the deoxyerythronolide B synthase (DEBS) 1 and DEBS3 enzymes in order to utilize the multi-catalytic capability of the modular polyketide synthase ([@B283]).

*Escherichia coli* has also been the pioneering host for recombinant protein production. To date, *E. coli* continues to be the first-choice microorganism for manufacturing recombinant proteins at laboratory and industrial scales. Its success is mostly due to its fast growth, simple culture procedures, cost-effectiveness, unusually high versatility, and the associated systems that make it adaptable to varying production demands ([@B67]; [@B203]). From 2004 to 2013, 24% of the biopharmaceuticals approved by the FDA and the European Medicines Agency were derived from *E. coli* ([@B8]). Currently, biopharmaceuticals produced from *E. coli* are used in the treatment of diabetes, growth hormone-deficiency in children, leukemia, gout, and many other therapeutic indications as previously discussed in Section "Biological Activity of Microbial Biologics" ([@B7]). A major concern when using *E. coli* as a production platform is the lack of post-translational modifications (PTMs) present in most eukaryotic proteins; lacking PTMs can lead to protein products being insoluble, unstable, or inactive ([@B66]). However, it is possible to add synthetic PTMs to generate versions of the protein that are more stable than the original naked product ([@B66]). Examples of this include pegylated products, like human growth hormone, stimulating factor, IFNs α-2a and α-2b, ([@B66]). Additionally, there is a risk of translational errors due to the presence of a large number of rare codons that appear in human genes that are different from those occurring in *E. coli* genes. Even at low levels, these errors may cause an impact on the tertiary structure, premature termination of protein synthesis or amino acid misincorporation which results in low protein expression ([@B88]). One strategy to bypass the issue with codon bias is to synthesize the whole human gene based on codon usage in *E. coli* through site-directed mutagenesis, which is currently a preferred method; however, it is limited by the high cost of production and time consumption ([@B232]). An alternative method that is less time consuming utilizes the co-transformation of *E. coli* strains with a plasmid(s) containing a gene encoding the tRNA cognate to the rare codons ([@B55]). Increasing the copy number allows for *E. coli* to be manipulated to match the codon usage frequency in heterologous genes ([@B55]). Currently, there are numerous commercial *E. coli* strains available that harbor plasmids containing gene sequences encoding the tRNA for rare codons, such as BL21(DE3) CodonPlus-RIL, BL21(DE3) CodonPlus-RP and Rosetta (DE3) ([@B7]). Another common problem associated with recombinant protein expression in *E. coli* involve inclusion body formation, which refers to insoluble and inactive protein aggregates ([@B91]). *E. coli* producing recombinant proteins have the ability to assemble in cells and form conglomerates of inclusion bodies as well as result in erroneous protein folding which hinder the extraction of proteins directly from the cell leading to costly purification of proteins ([@B291]). Inclusion bodies formed from lack of proportion between protein solubilization and aggregation can be resolved by combining the desired protein with a solubility enhancer fusion partner acting as an intrinsic chaperone in order to ensure the production of soluble recombinant proteins ([@B201]). The fusion of maltose-binding protein to polypeptides such as human tissue inhibitor of metalloproteinase and p16 improved their solubility significantly in *E. coli* ([@B114]).

Gram-Positive Bacteria
----------------------

### Lactococcus lactis

*Lactococcus lactis* is becoming an attractive alternative in genetic engineering for the production of various recombinant proteins. Unlike *E. coli*, which uses intracellular production strategies that involve expensive and often challenging purification processes, *L. lactis* utilizes extracellular secretion system. This is because *L. lactis* has a monolayer cell wall that allows direct secretion into the extracellular environment ([@B209]). The presence of exported proteases such as HtrA in *L. lactis* contributes to recombinant protein production by minimizing the destruction of heterologous proteins in the medium ([@B162]; [@B229]). Additionally, *L. lactis* does not generate undesired glycosylation of protein, is generally recognized as safe (GRAS), does not produce endotoxins, and has probiotic properties ([@B224]). Another advantage of *L. lactis* includes a lack of inclusion body formation ([@B245]). There is a diverse selection of cloning and inducible expression vectors available for use with this host that are compatible with large-scale upstream and downstream processes ([@B229]).

*Lactococcus lactis* has been used for centuries in the fermentation of food, especially in cheese, yogurt, and sauerkraut because of its production of nisin ([@B229]; [@B224]). Beyond the food industry, lactic acid is used as an emulsifier and moisturizing agent in the cosmetic industry and as an important raw material in the pharmaceutical industry ([@B184]). The *L. lactis* host has also been chosen after researchers had unsuccessfully attempted to obtain correct conformation using a variety of other prokaryotic and eukaryotic recombinant protein expression systems. *L. lactis* has multiple advantages over *E. coli* for expression of 5′-methylthioadenosine/*S*-adenosylhomocysteine nucleosidase (*Pfs*) recombinant proteins, including the following: (1) codon-optimization of the recombinant gene is not necessary to achieve successful expression in *L. lactis*; (2) the recombinant protein is secreted into the *L. lactis* culture supernatant, which results in easier and less expensive down-stream processing, and (3) there is no lipopolysaccharide contamination in *L. lactis* expression ([@B224]). *L. lactis* has been used in the successful production of recombinant *Pfs48/45*, a vaccine candidate against *P. falciparum* ([@B229]). GMZ2, a recombinant fusion protein expressed in *L. lactis*, is also a malaria vaccine candidate that has been shown to elicit high levels of active IgG antibodies with inhibitory activity against a broad range of *P. falciparum* strains ([@B106]). A recent study concluded phase 2 trial of GMZ2 adjuvanted with aluminum hydroxide in a cohort of 1,849 children revealed GMZ2 as well tolerated with modest efficacy ([@B225]). Not only is *L. lactis* being utilized for the production of recombinant proteins for vaccines, but the host is also being tested as a factory for antigen production, allowing the bacteria to function as live vaccines. Using *L. lactis* as a vaccine carrier is beneficial because it can induce both mucosal and systemic immune responses, has adjuvant properties and is free from the risks associated with the use of conventional attenuated live pathogens, such as *Salmonella* species and *Mycobacterium* species ([@B229]). However, while *L. lactis* has been studied against an array of antigens from various pathogens, there is no current live vaccines under clinical trial which may be due to a lack of containment strategies ([@B9]). Without a plan for containment, studies on live *L. lactis* vectors risk the chance of proliferation and dispersion. An additional limitation of AT rich *L. lactis* as a cell factory is due to codon usage as well as distribution of rare codons to express heterologous genes ([@B155]).

### *Streptomyces* Species

Another major species that has shown promise as a cell factory through its wide production of natural products and biologics is *Streptomyces*. This Gram-positive bacterium has been studied for more than 70 years and has proven to be of great use in biotechnology due to its ability to produce natural products acting as antibiotics, anticancer agents, and immunosuppressants ([@B275]). Some examples include tetracycline, daptomycin, and chloramphenicol ([@B47]). There are many species of *Streptomyces* currently to produce various natural products and biologics. Among the *Streptomyces* species, *Streptomyces coelicolor*, *Streptomyces lividans*, *Streptomyces albus*, and *S. venezuelae* are favored heterologous hosts to produce specialized metabolites due to the relative ease of their genetic manipulation, the availability of their genome sequences, and the abundant supply of their natural substrates ([@B186]). *Streptomyces* has also been used to produce a wide array of heterologous proteins of both eukaryotic and prokaryotic origin ([@B79]) because *Streptomyces* has well-developed genetic manipulation and fermentation technologies as well as efficient protein secretion systems such as the secretory (Sec) pathway and the twin-arginine-translocation (Tat) pathway ([@B90]). The Sec-pathway catalyzes the translocation of unfolded proteins while the Tat pathway allows for the export of folded proteins across the cytoplasmic membrane ([@B172]). Tumor necrosis factor (TNF) α and human interleukin (hIL) 10 are able to be expressed in both the Sec- and Tat-pathways ([@B204]). In particular, *S. lividans* could be the ideal *Streptomyces* host due to limited restriction-modification systems and low endogenous protease activity ([@B168]). Streptokinase ([@B196]), transforming growth factor-α ([@B238]), IL-2 ([@B18]) and many other proteins have been successfully expressed and secreted from *S. lividans.* However, aside from its efficient secretory pathways, when in culture, *Streptomyces* grows as mycelial networks, leading to the formation of pellets or clumps ([@B253]). These pellets are unappealing from an industrial standpoint because of mass-transfer problems, slow growth, and culture heterogeneity which leads to lower product yield ([@B253]).

### *Bacillus* Species

*Bacillus* species are some of the most popular species used in enzyme production. It accounts for roughly 50% of enzymes market within the industrial sphere ([@B13]). Certain species, like *B. subtilis*, *Bacillus amyloliquefaciens*, and *B. licheniformis* are favored because of their outstanding fermentation properties, high protein production yield, and their completely toxin-free production ([@B253]). The fermentation capacity of *Bacillus* species in acid, neutral, and alkaline pH ranges in addition to thermophiles accounts for the prolific production of enzymes that have desirable temperature, pH, and stability, which makes them appealing for specific use in various industries ([@B205]). *Bacillus* species are known for their production of iturins and fengycin which have antifungal activity as well as surfactin for its function as a surfactant ([@B262]).

Among these species, *B. subtilis* is the most widely studied due to (1) its flexibility during genetic engineering, (2) its naturally high secretory capacity, (3) its ability to produce valuable antibiotics, such as bacillomycins D-L and bacitracin, and (4) its ability to produce enzymes, such as stable alkaline cellulase, alkaline protease and alkaline α-amylase. It may also elicit better folding conditions, leading to the prevention of inclusion bodies ([@B194]; [@B252]). In addition, its ability to adapt to varying environmental conditions as well as its classification as toxic free GRAS has contributed tremendously to its success in the industrial platform ([@B15]). *B. subtilis* as an endotoxin free host amplified its utilization in the production of sterile recombinant and therapeutic proteins expression as compared to *E. coli* which could have potential contamination due to the lipopolysaccharide endotoxins ([@B263]). For instance, *B. subtilis* and *Bacillus megaterium* were the preferred hosts over *E. coli* in the production of bioengineered heparin in order to diminish toxin contamination ([@B263]). Moreover, *B. subtilis* is able to produce high yield in enzyme as it secretes the enzymes straight into the fermentation medium due to the absence of outer membrane which allows easy recovery of purified proteins from the medium into their active form ([@B291]). It has the capacity to secrete about 20--25 g/L of enzymes into the medium ([@B205]). Enzymes produced by *B. subtilis* has a wide variety of applications ranging from pharmaceutical, leather, detergent, food, and waste management industries ([@B221]).

Aside from enzyme production, cytokines like hIL-3 have been produced by *B. subtilis* and *B. licheniformis*. The production of hIL-3 has been tested in various host organisms, including *E. coli*. However, the production of IL-3 within other organisms has often exhibited problems, such as insolubility or the degradation of produced hIL-3. This led to the use of *B. licheniformis* and *B. subtilis* to minimize such complications. The production of hIL-3 in *B. licheniformis* was engineered to lack four C-terminal residues, resulting in a fully active hIL-3 protein. However, residual proteolytic degradation of some hIL-3 still occurred, leading to use *B. subtilis* to achieve complete folding and full biological activity of hIL-3 ([@B267]).

Among the *Bacillus* species, *Bacillus thuringiensis* is best known for being widely used within the agricultural industry due to its insecticidal properties through its production of parasporal crystals during the stationary phase of its growth cycle ([@B97]; [@B210]). Upon ingestion, the parasporal crystals are solubilized in the midgut of insects, resulting in the release of protoxin proteins known as δ-endotoxins, leading to the formation of pores throughout the cell membrane ([@B97]; [@B80]). Parasporal proteins also have selective cytotoxicity against liver and colon cancer cells while leaving normal cells unharmed ([@B104]).

However, the use of *Bacillus* has been restricted to mainly enzyme production and non-recombinant protein therapeutics, which may be due to the lack of associated expression vectors, plasmid instability and the presence of native proteases ([@B268]). Despite *B. subtilis* success as the industrial workhorse, it has its drawbacks in the production of heterologous proteins. Heterologous protein yield could diminish when using the *Bacillus* as a host due to the proteolytic destruction of foreign protein by host secreted extracellular proteases ([@B176]). Efforts have been made to improve the production of heterologous protein by manipulating the expression of proteins involved in the post translocation phase resulting in amplified levels of heterologous protein secretion ([@B256]). In contrast to *E. coli*, the absence of distinguished and controllable promoters in *B. subtilis* interferes with successful expression of heterologous genes resulting in inefficient production of heterologous proteins ([@B205]).

Yeast/Fungi
-----------

### Saccharomyces cerevisiae

As with *E. coli*, *S. cerevisiae* has been extensively used for the production of recombinant human insulin since the early 1980s, and it currently produces half of the world's supply of insulin ([@B152]). *S. cerevisiae* is preferred because it is also cost-effective, fast growing, technically practical, and is amenable to large-scale fermentation in bioreactors. Yeast is often utilized as a cell factory when the target protein is not produced in a soluble form in prokaryotic systems or when a specific PTM cannot be produced or added to the naked product. *S. cerevisiae*, as with other yeast species, can perform many PTMs such as *O*-linked glycosylation, phosphorylation, acetylation, and acylation, which allows recombinant proteins to be expressed in a soluble, correctly folded, and functionally active form ([@B66]; [@B8]). Some examples of currently approved protein therapeutics derived from yeast include human serum albumin, insulin, and primary immunization for infants born of HBV surface antigen, all which are obtained in *S. cerevisiae* ([@B147]; [@B10]; [@B175]; [@B169]). However, the significant drawback to producing protein therapeutics from *S. cerevisiae* is that higher eukaryotes have a different pattern of *N*-linked glycosylation, which can decrease the half-life and cause hyper-immunogenicity, leading to less effective therapeutics ([@B66]). In recent years, there have been some advances in limiting *S. cerevisiae* hypermannosylation. These yeast glycoengineering techniques involve two main stages, (1) the removal of yeast hypermannosylation and (2) the conversion to complex glycoforms containing terminal sugars, such as *N*-acetylglucosamine, galactose, or sialic acid. These recent reports on yeast *N*-glycan humanization indicate a move from the proof of concept phase to implementation ([@B152]).

Another current area of study is the production of plant and microbe-derived secondary metabolites. Due to the structural complexity of secondary metabolites, chemical synthesis is an inefficient route for large-scale production, and fermentation is the main mode for economic commercial production of pharmaceutically useful natural products ([@B148]). *S. cerevisiae* could be an ideal candidate as a microbial host as it boasts relatively rapid growth, and it is accompanied by highly developed genetic tools and advanced fermentation science. Like *E. coli*, *S. cerevisiae* has been shown to be an outstanding production host for artemisinic acid, a precursor to the antimalarial agent artemisinin, with a high productivity (25 g/L) that led to the industrial production of semi-synthetic artemisinin beginning in 2013 ([@B179]; [@B125]). Research has also produced the paclitaxel (Taxol^®^) precursor taxadiene (∼73 mg/L) by engineering the taxol biosynthetic genes in *S. cerevisiae* ([@B56]). Besides plant secondary metabolites, *S. cerevisiae* has generated a remarkable titer (1.7 g/L) of microbial polyketide 6-methylsalicylic acid in un-optimized shake-flask fermentations. In addition, *S. cerevisiae* has been developed as a heterologous host to express fungal cryptic BGCs and their respective metabolites. In this study, 30 *ADH2*-like promoters in *Saccharomyces* species were developed as tools for expression of 41 heterologous BGCs, 22 of which were capable of producing heterologous compounds, including novel compounds. For example, BGCs derived from basidiomycete were found to produce *N*-, *S*-bis-acylated amino acids and a leucine *O*-methyl ester with an additional polyketide chain amidated to the amino ester ([@B92]). However, barriers still exist to the heterologous production of complex molecules. This includes the production of polyketides in *S. cerevisiae*, as the host lacks some required polyketide precursor pathways, its codon usage is biased toward A + T (most microbial polyketide producers have high G + C genome content) and it lacks the appropriate endogenous phosphopantetheinyl transferase capable of the necessary PTMs ([@B167]).

### *Aspergillus* Species

Multicellular filamentous fungi, such as *A. niger* and *Aspergillus oryzae*, can also offer great potential in the production of a desired substance by fermentation due to the following reasons: (1) they are well-characterized GRAS organisms, (2) are amenable to scaled-up fermentation, (3) can be genetically engineered, (4) they are capable of secreting a high level of proteins and (5) can withstand adjustable cultivation conditions, including temperature (5--45°), pH (2--11), salinity (as much as 34%), water activity (0.92--0.98), and both nutrient rich and poor environments ([@B139]; [@B154]).

*Aspergillus niger* has been predominantly used for industrial-level production of citric acid through anaerobic fermentation process. As a weak acid, citric acid can serve as a natural preservative, flavoring agent in food and beverages, antioxidant, acidulant, pH-regulator, chelating agent or vegetable rinse, as well as comparable applications in the pharmaceutical and cosmetics industries ([@B29]). Due to its wide variety applications, its ease of production, and economical potential of citric acid, the market of citric acid has become one of the fastest-growing regions of the food additives market due to the rising demand: according to estimations, in 2007, the market value of citric acid exceeded \$2 billion in 2014 and is predicted to rise to \$3.6 billion by 2020 ([@B217]; [@B29]). Phytase is another example that have produced by *A. niger* fermentation ([@B185]). The significance of phytase enzymes lie in its ability to interact with the nutrient rich compounds known as phytate. Phytate, or phytic acid, is a common energy source found in oilseeds, cereals, and legumes, which are used in providing nutrition to animal feeds ([@B207]). Combining citric acid with phytase has also been shown to enhance phytase activity on phytate, producing greater nutrient outcomes in tested animals ([@B23]). In addition, two different humanized immunoglobulin G1(κ) antibodies and an Fab′ fragment were produced by *A. niger*, and the antibodies were successfully secreted into the culture supernatant ([@B264]). *Aspergillus* strains have been also used to produce the human iron-binding glycoprotein lactoferrin and hIL-2 with the yields of 25 and 150 mg/L, respectively ([@B139]). Bicoumanigrin with cytotoxic activity against human cancer cell lines and aspernigrin B with neuroprotective effects have both been isolated from *A. niger* ([@B96]). The product spectrum of *Aspergillus* species is not restricted to biologic molecules. As an example, a novel cyclic peptide compound, KK-1, with potent antifungal activity was produced in *A. oryzae* by introducing gene clusters spanning approximately 40 kb from the plant-pathogenic fungus *Curvularia clavata* into the genome of *A. oryzae*. Although the amount of KK-1 produced by the host was lower than that produced by the original producer *C. clavata*, this result indicated that a gene twice as large as the largest native gene in *A. oryzae* could be successfully expressed ([@B278]). Furthermore, when the industrial fungus *A. niger* was engineered as a heterologous host, it produced high titers (up to 4,500 mg/L) of enniatin belonging to non-ribosomal peptides with antibacterial, antiviral, and anticancer activities ([@B199]).

### Hansenula polymorpha

Another industrially important yeast species that has shown promise in the production of peptides is *Hansenula polymorpha* ([@B76]; [@B22]). *H. polymorpha* is a methylotrophic yeast species with the ability to use and grow on methanol, glucose, or glycerol as its primary carbon source ([@B76]). Like *S. cerevisiae* and *Aspergillus* species, *H. polymorpha*, classified as GRAS organism, does not harbor pyrogens, toxins, pathogens, or viral inclusions ([@B249]). It is distinguished by very high cell densities in bioreactors and characterized by simple cultivation mode in inexpensive growth media. For example, *H. polymorpha* has allowed for cost-effective production of phytase through cheap carbon sources ([@B146]). It possesses well-established genetic tools such as strong regulatory and constitutive promoters, which consequently give high product yield ([@B251]). It also has thermotolerance properties, making *H. polymorpha* successful in crystallographic studies and in the production of recombinant proteins like IFN-2α, IL-6, recombinant human serum albumin, glucose oxidase, and catalase ([@B126]; [@B31]). A notable feature of *H. polymorpha* is the significant growth of peroxisomes when grown on methanol which allows for high storage capacity of soluble proteins. The lack of protein modifying enzymes in the matrix of peroxisomes also provides an advantage for the development of heterologous proteins that are susceptible to proteolytic degradation ([@B251]). Furthermore, the host has been used to produce L antigens found on the HBV viral envelope in attempt to produce the HBV vaccine. The L protein produced by *H. polymorpha* has increased stability in comparison to other yeast species, such as *S. cerevisiae* and *P. pastoris* ([@B105]). In addition to its use in vaccine production, *H. polymorpha* is also used in the production of human hemoglobin through the use of a single expression vector ([@B98]). However, hyperglycosylation has been observed as a main drawback of *H. polymorpha* to produce heterologous products ([@B165]).

Efforts in Product Improvements and Generation of New Analogs
=============================================================

There are multiple approaches that have been taken to advance product improvement for microbial natural products and biologics. This section will discuss efforts to combat the challenges of production of natural products and its analogs, including strain improvement, increasing precursor supply, pathway engineering, combinatorial biosynthesis, and genome mining ([Figure 5](#F5){ref-type="fig"}).

![An overview of multiple strategies of product improvements and generation of new analogs.](fmicb-10-01404-g005){#F5}

Strain Improvement
------------------

Whole-genome shuffling is a process that utilizes the advantages of the multi-parental crossing allowed by DNA shuffling with the genome recombination normally associated with conventional breeding ([@B286]). Genome shuffling has been successfully improved the titers of variety of microorganisms. For example, two strains of *Streptomyces fradiae* generated from two rounds of genome shuffling were able to produce up to a ninefold increase in antibacterial tylosin production in comparison to the initial strain ([@B286]). Using genome shuffling in a combination of protoplast fusion, mutant strain of *S. cellulosum* GSUV~3-205~ generated a 130-fold increase (104 mg/L) in production of epothilone when compared to starting strain *S. cellulosum* So0157-2 (0.8 mg/L) ([@B82]). Ribosome engineering is also a method useful in increasing secondary metabolite production titer and productivity ([@B236]). Studies demonstrate that *rpoB* mutations are effective in activating silent and poorly expressed secondary metabolite biosynthetic gene clusters (BGCs) at the transcriptional level in *S. griseus*, *S. coelicolor*, and *S. erythraea* ([@B177]). For example, the H437R mutant of *rpoB* from *S. erythraea* was screened for drug resistance and was found to have an increased production of erythromycin ([@B242]; [@B178]). Another study found a 37-fold increased production of avilamycin in a recombinant *Streptomyces viridochromogenes* strain due to a mutation in ribosome protein S12 (*rps12*) acquired through a combination of gene shuffling and ribosome engineering ([@B138]).

Engineering Precursor Supply
----------------------------

Precursor supply is defined as the enhancement of the availability of primary metabolites or molecules derived from primary metabolism involved in the biosynthesis of natural products ([@B214]). Precursor supply engineering can be achieved by manipulating either the pathways or enzymes involved with the precursor supply. Malonyl-CoA and methylmalonyl-CoA are the most commonly used and metabolically available precursors for the biosynthesis of polyketides. One study found that supplying methyl oleate enhanced the internal concentration of methylmalonyl-CoA, which is a biosynthetic precursor for FK506, and led to a 2.5-fold increase in FK506 production in *Streptomyces clavuligerus* CKD1119 ([@B158]). In another study, propionyl-CoA carboxylase with supplementation of propionate was found to effectively increase methylmalonyl-CoA and rapamycin titers in the mutant strain *S. rapamycinicus* UV~2-2~ induced by ultraviolet mutagenesis in comparison to wild-type strain (7 ∼ 8 mg/L) ([@B111]). The mutant strain was found to have a 3.2-fold improvement (23.6 mg/L) in comparison to wild-type strain *S. rapamycinicus* ATCC 29253 (7 ∼ 8 mg/L) ([@B111]). Further, Méndez and coworkers improved precursor metabolite pools for the production of the antitumor polyketide mithramycin in *Streptomyces argillaceus* by increasing the precursor supply of malonyl-CoA and glucose-1-phosphate ([@B280]). Several classes of natural products utilize aromatic amino acids or other metabolites derived from the shikimate pathway as precursors, including flavonoids, alkaloids, polyketides, and non-ribosomal peptides ([@B122]). The production of the vancomycin analog balhimycin was increased 2.5-fold in *Amycolatopsis* sp. Y-89,21022. This was achieved by increasing the non-ribosomal peptide precursor 3-deoxy-[D]{.smallcaps}-arabino-heptulosonate7-phosphate synthase, the first enzyme in the shikimate pathway ([@B247]). In addition, manipulating key enzymes that direct carbon flux through core biochemical pathways involved in glucose, fatty acid, and amino acid metabolism can increase biosynthetic precursor pools. A study on the modulation of carbon flux between the pentose phosphate pathway and the glycolysis pathway found that a deletion of phosphofructokinase isoenzymes led to the enhanced production of antibiotics actinorhodin and undecylprodigiosin in *S. coelicolor* by increasing carbon flux through the pentose phosphate pathway ([@B25]).

Precursor supply engineering has been successfully used to produce most of the major classes of natural products, with application to heterologous producing strains as well as native producers. When the native host is slow-growing or cannot be easily manipulated genetically, this process could be performed effectively in an appropriate heterologous host. A study bypassed the native deoxyxylulose 5-phosphate pathway and instead introduced the mevalonate pathway from *S. cerevisiae* to *E. coli*, which allowed for an increased production of amorpha-4,11-diene which is a precursor to antimalarial artemisinin ([@B143]). Combined approach of exogenous supplementation and engineering of intracellular pathway responsible for precursors can be also performed in a heterologous host. The biosynthetic process of the hybrid non-ribosomal peptide-polyketide yersiniabactin was known to rely on the supply of salicylate, [L]{.smallcaps}-cysteine, *S*-adenosyl-[L]{.smallcaps}-methionine, malonyl-CoA, and NADPH. When exogenous cysteine was fed to the culture of *E. coli* harboring yersiniabactin BGC and an additional set of genes (*hmwp1-2*) responsible for yersiniabactin precursor biosynthesis was introduced, the yersiniabactin production in *E. coli* was boosted to approximately 175 mg/L ([@B3]).

Precursor engineering strategy can be also employed to increase recombinant protein production by reducing unwanted by-products. One of the primary obstacles observed in high cell density cultivations of *E. coli* for the production of recombinant proteins is the formation of acetate, which is a by-product caused by an excess influx of carbon during aerobic fermentation. This acetate accumulation hampers cell growth and recombinant protein formation, even at low concentrations ([@B258]). A number of engineering approaches have focused on minimizing acetate formation in order to enhance recombinant protein production in *E. coli*. When a heterologous anaplerotic pyruvate carboxylase from *Rhizobium etli* is overexpressed in *E. coli*, the resulting strain had a 57% reduction in acetate formation and a 68% increase in β-galactosidase production ([@B142]). It is also possible to combine different strategies to reduce the formation of undesired by-products, including acetate. For example, one study found that a mutant *E. coli* strain containing a defective acetate pathway and an overexpressed phosphoenolpyruvate carboxylase-encoding *ppC* reduced acetate and other by-product formation and produced five time more β-galactosidase activity when compared the wild type strain ([@B48]).

Pathway Engineering
-------------------

Metabolic pathway engineering can be performed in the native host through repetitive gene expression, gene deletion, and introduction of new genes to enhance production of natural products ([@B195]). For example, overexpression of the 4--12 tandem copies of the actinorhodin cluster resulted in a 20-fold increase in actinorhodin production in *S. coelicolor* ([@B166]). Additionally, a *S. hygroscopicus* strain with 3--5 tandem copies of the 40 kb validomycin A cluster showed a 34% increase in production and a maximum titer of approximately 20 g/L ([@B288]). Deletion of genes may be useful to eliminate competing pathways that may siphon off important precursors or intermediates, or simply contribute to an unnecessary use of cellular resources which result to improve yields of products of interest. During *in vivo* bioconversion of lovastatin intermediate monacolin J to simvastatin using *E. coli* expressing heterologous acyltransferase LovD, it was found that *E. coli* could unexpectedly hydrolyze the synthetic thioester substrate. The responsible hydrolase BioH was knocked out to improve simvastatin production ([@B273]). The regulatory component of the pathway can be manipulated to enhance production of the resulting natural product. Negative regulation by pathway specific repressors can help regulate secondary metabolite pathways. For example, one study improved the titer by 100-fold of antibiotics platensimycin (323 mg/L) and platencin (255 mg/L) through the inactivation of a gene encoding protein PtmR1 belonging to GntR family of transcriptional repressors ([@B227]). On the other side of the spectrum, *Streptomyces* antibiotic regulatory protein (SARP) is a positive regulator of antibiotic production ([@B36]). Overexpression of SARPs and/or increasing SARP gene dosage using multi-copy plasmids has been demonstrated to increase production titers. Overexpression of *mgsA* or *chxA*, SARP family members that are positive regulators for the iso-migrastatin and cycloheximide biosynthetic machinery, respectively, in *Streptomyces amphibiosporus* ATCC 53964 led to a fivefold increased production of antibiotic lactimidomycin ([@B282]). Members of the large ATP-binding regulators of the LuxR (LAL) family also generally function as transcriptional activators, and constitutive overexpression of these LAL-type activators was found to increase production of rapamycin in *S. rapamycinicus* and FK506 in *S. tsukubaensis* ([@B127]; [@B159]).

Competing pathways can also be deleted to ensure the production of important precursors or intermediates and to save useful cellular resources. When deleting pathways, the idea is to create a host with a minimized genome to ensure the efficient production of necessary secondary metabolites. Deleting non-essential genes and directing cellular resources toward pathways that are essential for the survival and product biosynthesis can improve cellular efficiency and streamline biochemical production. For example, the genome of *Streptomyces avermitilis* was effectively minimized to 83% of its original size. When heterologous streptomycin gene cluster was introduced into the genome-minimized *S. avermitilis*, the resulting strain produced a higher titer of streptomycin than both the parent *S. avermitilis* carrying the same heterologous gene cluster and the native streptomycin producer *S. griseus* ([@B124]). However, large scale deletions may result in unintended effects as the complete workings of the cell are not yet entirely understood.

Similar approaches have been employed to improve the secretion capability and productivity of biologics. Engineering the protein trafficking pathway represents one successful approach to improve the secretion of heterologous recombinant proteins. For example, the secretion of the heterologous proteins human insulin precursor and α-amylase from *A. oryzae* in *S. cerevisiae* was improved by the over-expression of Sec1/Munc18 proteins, which are involved in the protein secretory pathway ([@B101]). Increasing the copy number of genes that are associated with protein secretion can also enhance protein secretion. This is seen with the *Necator americanus* secretory protein (Na-ASP1), which shows potential as a vaccine protein for hookworm infections. Increasing the Na-ASP1 gene copy number caused saturation of secretory capacity in *P. pastoris*, a species of methylotrophic yeast, led to a decreased amount of secreted protein. This was remedied by the overexpression of the protein disulfide isomerase, which allowed for the increased secretion of Na-ASP1 protein in high copy clones ([@B103]). Another study showed that deletion of obstructive protease genes involved in fission could lead to the enhanced secretion of protease-sensitive human growth hormones (hGH) in *Schizosaccharomyces pombe*. The production of hGH was hampered by the intracellular retention of secretory hGH, and it was determined that the multi-protease deletant strain plays a role in hGH retention. Deletion of *vps10*, which encodes a carboxypeptidase Y sorting receptor and is involved in the traffic between the late-Golgi and prevacuolar compartments, resulted in an approximate twofold increase in hGH secretion ([@B102]).

Combinatorial Biosynthesis
--------------------------

Combinatorial biosynthesis is one genetic engineering application that can modify biosynthetic pathways in order to yield new and altered natural product structures ([@B100]). This approach exploits indiscriminate substrates and uses engineered enzymes and pathways for the production of new natural product analogs.

Modular megasynthases, such as PKS and NRPS enzymes, constitute a class of multifunctional proteins that govern complex enzymatic mechanisms and catalyze multiple reactions useful for combinatorial biosynthesis. Type 1 PKSs consist of multiple modules which are responsible for incorporating acyl-CoAs into a polyketide backbone for elongation. Meanwhile, NRPSs are composed of a modular set of repeating enzyme domains for the activation and incorporation of amino acids ([@B190]). The modular NRPSs typically consist of a condensation domain, adenylation domain, and a thiolation domain, while type I PKSs generally contain a ketosynthase domain, acyltransferase domain, and an acyl carrier protein ([@B123]; [@B226]). Natural product structures can be modified by mixing and matching the megasynthases at the subunit, module, and domain levels. Genetic manipulation of PKS and NRPS encoding genes can result in predictable changes in structure that is difficult to achieve with standard chemical derivatization or total synthesis methods ([@B186]). This approach to manipulating substrate incorporation and biosynthetic PKS and NRPS machinery has allowed for the generation of a great number of natural product analogs. Examples include erythromycin ([@B149]), pikromycin from type I modular PKS ([@B277]) and daptomycin from NRPS ([@B200]).

Post-assembly modifications, such as glycosylation, oxidation, and halogenation are performed by diverse enzymes and can lead to structurally and biologically diverse natural compounds ([@B186]). Sugar moieties attached to the core structure of polyketides or non-ribosomal peptides by glycosyltransferases can also contribute to an extension of combinatorial biosynthesis. Since several glycosyltransferases have been known to be flexible toward sugar donors and sugar accepters, arrays of analogs differing in glycosylation patterns via tailoring enzymes can also be generated by combinatorial engineering of glycosyltransferases from different pathways. For example, one study found that *A. orientalis*-derived glycosyltransferases accepted the unnatural sugar 4-*epi*-vancosamine in the presence of vancomycin pseudoaglycone or the glucosylated teicoplanin scaffold to generate novel hybrid glycopeptide compounds such as 4-*epi*-vancosaminyl form of vancomycin ([@B137]). Besides sugar biosynthesis, combinatorial biosynthesis can be applied for other modifications such as oxidation and halogenation. Oxidase genes from polyketide pathways have been used to induce structural alterations of important functional groups that are essential for biological activities. It has been reported that 5-*O*-desosaminyl erythronolide A, a potent precursor of ketolides and the latest generation of antibiotic compounds derived from erythromycin A, was produced by expressing the monooxidase gene *pikC* from the pikromycin pathway in a mutant strain of *S. erythraea* lacking of a EryBV glycosyltransferase ([@B14]). In addition, a recent study obtained nine analogs of the antitumor antibiotic xantholipin through the individual in-frame mutagenesis of five tailoring enzymes ([@B285]). In another study, fluorosalinosporamide, a derivative of the potent anticancer agent salinosporamide A, was produced by replacing the chlorinase gene *salL* from *Salinispora tropica* with the fluorinase gene *flA* from *Salinispora cattleya* ([@B64]).

However, a common concern with this approach regards limited tolerance of downstream enzymes or domains to the new substance introduced by combinatorial biosynthesis and metabolic engineering. Rational design or directed evolution is one solution to this concern. Rational design is the strategy of creating new molecules with a certain functionality based on predicting how the molecule's structure will affect its behavior, while directed evolution refers to methods to alter enzyme function using mutagenesis and selection ([@B170]). In a recent study, the reactivity of PikC was modified through protein engineering driven by molecular dynamics and quantum mechanical calculations. The computation-driven PikC engineering yielded a PikC~D50N~ mutant that showed improved catalytic efficiency compared to the wild-type PikC ([@B171]). This study demonstrated that a rationally designed protein using a crystal structure of protein and/or a computational analysis can develop a predictive model for substrate scope and selectivity of natural product biosynthesis-mediated reactions. Directed evolution is also a powerful tool to modify the activity of key enzymes responsible for the biosynthesis of natural products and can lead a higher diversity of natural products by generating novel and more potent analogs ([@B269]). As an example, a few rounds of directed evolution restored and enhanced the activity of an impaired chimerical enterobactin NRPS that has been swapped with a non-cognate aryl-carrier protein ([@B289]). In order to reduce the risk of limited tolerance and reduce concerns of efficiency, directed evolution requires a large, high-quality library and an efficient screening strategy. The swapping of functional domains often results in non-functional or heavily impaired chimerical enzymes, and this remains an existing problem when manipulating modular PKS and NRPS systems.

Mutasynthesis
-------------

Novel natural product analogs can also be generated through gene disruption and mutasynthesis. Disruption of a gene, such as a tailoring enzyme acting downstream in a pathway, can serve to introduce a structural change. Two FK506 analogs, 9-deoxo-31-*O*-demethylFK506 and 31-*O*-demethylFK506, were produced by targeting gene disruption in *Streptomyces* sp. MA6548 ([@B211]; [@B12]). These two recombinant mutants were genetically engineered via disruption of *fkbD* and *fkbM* genes that code for 31-*O*-demethylFK506 methyltransferase and 9-deoxo-31-demethylFK506 hydroxylase/oxidase ([@B211]; [@B12]). Inactivation of individual domains within the multidomain modular PKSs and NRPSs serves as an alternative to the deletion of a whole gene. Mutasynthesis involves the coupling of a gene inactivation strategy with precursor feeding to generate new structural analogs. Precursor feeding is useful due to the substrate-promiscuity of the biosynthetic enzyme. Precursor feeding may lead to the acceptance of similar substrates or mutasynthons, a natural substrate substitute that can replace the natural substrate of a disrupted gene after being added to the growth medium, to ultimately generate new analogs. Mutasynthesis can generate new analogs for many classes of compounds. For example, the analog cahuitamycin D was produced through mutasynthetic generation with twofold-enhanced biofilm inhibitory activity in comparison to its natural product counterpart ([@B189]). Recently, this approach was applied to generate nonbenzoquinone analogs of the Hsp90 inhibitor geldanamycin, which has anti-proliferative activity on tumor cells ([@B215]; [@B272]). By removing the biosynthetic genes for the 3-amino-5-hydroxybenzoic acid starter unit and feeding the culture with various 3-aminobenzoic acids and related heterocycles, a chloro-substituted nonbenzoquinone analog with significantly improved therapeutic properties was produced along with other geldanamycin analogs ([@B120], [@B119]). This has been also seen in the generation of new analogs of rapamycin ([@B116]), balhimycin ([@B266]), and novobiocin/chlorobiocin ([@B135]).

Future Prospects
================

An increasing number of natural products and natural product-derived compounds have been launched over the years ([@B28]). Since 2000, 77% of FDA-approved antibiotics are natural products, all of which were derived from microbes ([@B191]). There have been extensive reviews of natural products, semi-synthetic natural products, and nature-inspired molecules currently approved by the FDA that show the continued importance of natural products for medicine and health ([@B202]; [@B173]). Microbial biologics are expected to remain prominent in the global biologics market, which was valued at 277 billion USD in 2015 and was recently estimated to reach 400 billion USD by 2025 ([@B84]). While many of the biological activities of microbial natural products and biologics are well known, new advances and insights continue to be discovered. Chemical diversity from microbial natural products continue to be relevant to future drug discovery, with a continuing need for novel drugs with antibiotic, anticancer, and immunosuppressant effects, along with other pharmacological activities ([@B202]).

At the same time, there are a multitude of challenges facing microbial production of natural products and biologics. Some challenges to natural products-based drug discovery involve low production titers, difficulty in product isolation or structural identification. Similarly, there is much room for improvement in terms of the expression of recombinant proteins in microbial platforms. Accumulation of the end product in the microbial cell can cause global stress responses that result in cell growth inhibition. Also, the formation of misfolded and biologically inactive proteins can lower the yield of recombinant proteins. In particular, membrane proteins, high-molecular weight proteins, and multi-domain proteins are often expressed in inclusion bodies. Additionally, expressing eukaryotic proteins in a prokaryotic-based heterologous system can result in a product that is not correctly modified by post-translational enzymes, which are often required for functionality ([@B201]). However, a wide variety of engineering strategies can be used with the conventional recombinant DNA technologies, including genome editing, ribosome engineering, precursor engineering, mutagenesis, and overexpression of structural genes, making it possible to facilitate the efficient production of natural products and pharmaceuticals in microbial systems.

Current technologies, such as CRISPR/Cas (Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR associated protein), should also be considered as tools for genome editing for additional improvements and to increase production ([@B74]). For example, *in vitro* CRISPR-Cas9 cloning with Gibson assembly has provided an alternate strategy for heterologous expression of cryptic BGCs from genetically recalcitrant actinomycetes strains ([@B261]; [@B107]). Additionally, CRISPR-Cas9 has many prospects in the analyses of biochemical pathways in *Streptomyces* strains due to the development of a pCRISPomyces expression system ([@B40]). With genome editing tools, it is also possible that non-model native hosts can be engineered to be heterologous production hosts to become platforms for combinatorial biosynthesis to create synthetic natural products and natural product derivatives. Some intrinsic limitations for non-model microbial hosts can be also improved by this genetic modification. *Corynebacterium glutamicum*, a GRAS organism, has been used for the industrial production of various amino acids for over five decades ([@B16]). Recently, it also showed promising potential for use as a protein expression system ([@B113]). However, this bacterium has intrinsic disadvantages, including a much lower transformation efficiency and lower yields of protein production. The CRISPR/Cas9 system was successfully employed to disrupt four different genes in *C. glutamicum*, opening new possibilities to use non-model strains as improved cell factories for the production of recombinant proteins and natural products ([@B193]).

Genome mining is another alternative process to discover secondary metabolites and is done by extracting information from genome sequencing ([@B6]; [@B287]). Evaluating silent cryptic BGCs through genome mining has provided valuable avenues to generate novel molecules. For example, a genome mining strategy combined with bioinformatics predictions was used to isolate the novel natural product orfamide A by feeding a predicted precursor to a culture of *Pseudomonas fluorescens* ([@B281]). In a recent study, genome mining-based combinatorial biosynthesis approach also led to the discovery of new members of the leinamycin family of natural products. Leinamycin has been considered a promising anticancer drug lead due to its potent anticancer activities, unique molecular architecture and interesting modes of action. However, no leinamycin analog had been isolated in the past three decades until this study ([@B181]).

A combination of approaches can also lead to improvements in the field of microbial natural products, such as gene shuffling and ribosome engineering for increased secondary metabolite production. Additionally, the integration of 'omics' information has great potential in natural product drug discovery, such as with metabolomics to accurately quantify biochemical changes and metabolic pathways. Advancements in metagenomics has allowed for further understanding of diverse and complex microbial sources, including lakes, rivers, marine environments and extreme conditions, such as sub-seafloor sites and ice cores ([@B33]).

In terms of structural characterization, X-ray crystallography and cryo-electron microscopy are advanced techniques that can allow for structure solving with high precision. Cryo-electron microscopy has been a leading method for evaluating macromolecular structures at near-atom resolution ([@B216]). For example, single particle electron cryo-microscopy has been used to visualize pikromycin PKS module 5 from *S. venezuelae*, which allowed for 3D map construction with resolutions of 7.3--9.5 Å to reveal secondary structures ([@B59]). These techniques are just a few among many that should be considered for structural studies on natural product biosynthesis. Advancements in computational strategies have led to the identification of BGCs in genome sequences and predictions of product chemical structures. Sequencing campaigns for natural product discovery should be directed toward samples likely to yield novel natural products along with well-characterized clades, such as actinomycetes, as they are still a resource for natural product discovery and have yet to be fully exhausted. The development of algorithms to mine the ever-increasing amounts of metagenomic data will allow for the potential of genome mining to be realized ([@B151]). Finally, developing additional host platforms for high-throughput refactoring and functional expression of pathways has the potential to overcome current limitations in precursor supply, product toxicity, the ability to express very large gene clusters and more ([@B208]).

Overall, microbial natural products and biologics will continue to broaden their diverse and integral role in human life. The potential for recombinant drugs is expanding through the utilization of new protein production platforms and efforts in product improvement. Microbial cells will remain as potent protein factories because of their versatility and cost-effectiveness. Engineering strategies and recombinant DNA technologies will also allow for the increased production of microbial natural products and recombinant proteins despite the many challenges faced. Continued efforts in natural product analog development will provide an avenue for the discovery of compounds with improved biological activities in comparison to their natural counterparts. Current advanced technologies can be utilized to further advance the field of microbial natural products, which remain a steadfast resource for novel compounds in drug discovery.
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